← Back to Search

Vaccine

Pneumococcal (PPSV23) vaccine for Inflammation (PREP DOD Trial)

Phase < 1
Waitlist Available
Research Sponsored by Texas A&M University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at enrollment
Awards & highlights

PREP DOD Trial Summary

This trial will help determine how to best predict when someone is about to get sick, so that we can take action to prevent it.

PREP DOD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~+14, +16, +21 days of enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and +14, +16, +21 days of enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Questionnaires, self-reported changes in general physical health, and physiological measurements to predict of type of vaccine administered
Secondary outcome measures
Amount of End-tidal Carbon Dioxide
Apnea
Assessment of the type and relative abundance of protein and lipids contained in Exhaled Breath Condensate
+62 more
Other outcome measures
Communicable Diseases
Development of personalized algorithm to provide an estimated index of severity of infection using activity and physiological measures
Development of personalized algorithm to provide an estimated score related to time until recovery of infection using activity and physiological measures
+1 more

PREP DOD Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Pneumococcal (PPSV23) vaccineActive Control1 Intervention
PNEUMOVAX 23 is a clear, colorless solution. Each 0.5-mL dose of vaccine contains 25 micrograms of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative under the supervision of a licensed pharmacist.
Group II: Typhoid (inactivated) vaccineActive Control1 Intervention
Typhoid vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection under the supervision of a licensed pharmacist.
Group III: SalinePlacebo Group1 Intervention
Saline will be purchased commercially and compounded under the supervision of a licensed pharmacist in sterile syringes for administration of the placebo group.

Find a Location

Who is running the clinical trial?

Texas A&M UniversityLead Sponsor
140 Previous Clinical Trials
23,857 Total Patients Enrolled
2 Trials studying Inflammation
20 Patients Enrolled for Inflammation
US Department of Defense - Defense Threat Reduction AgencyUNKNOWN
Philips HealthcareIndustry Sponsor
125 Previous Clinical Trials
282,077 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Persistent Readiness Through Early Prediction Immunization Study
Marielle PKJ Engelen, PhD 2022. "Persistent Readiness Through Early Prediction Immunization Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05346302.
~79 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top